WBA

Walgreens Launches Cheaper Version Of Opioid Overdose Reversal Spray Naloxone

(RTTNews) - Walgreens Boots Alliance, Inc. (WBA) made an announcement on Wednesday about the launch of its own more affordable version of the over-the-counter opioid overdose reversal spray naloxone.

This new product, Walgreens Brand Naloxone HCl Nasal Spray, is set to be available both online and in all stores by the end of the month.

This move aims to address the opioid epidemic and the high rates of drug-related fatalities in the United States by increasing the availability of this life-saving medication.

The Walgreens Brand Naloxone HCl Nasal Spray is designed to temporarily reverse the effects of opioids during an overdose, including heroin, illicit fentanyl, and prescription opioid medications.

The spray works by blocking the effects of opioids on the brain, thereby restoring normal breathing and preventing death.

Despite its effectiveness, access to naloxone is limited in many communities, exacerbating the impact of the opioid epidemic. To tackle this issue, Walgreens is making naloxone more accessible by offering it at a lower price than the national brand equivalent in its stores.

Priced at $34.99, the product is available online now, with nationwide availability in stores scheduled by the end of the month. It will be located in the pain aisle, providing a crucial access point for the millions of individuals served by Walgreens daily across the U.S.

According to the Centers for Disease Control and Prevention, naloxone is safe for bystanders to administer during a suspected overdose and poses no harm if the individual is not actually experiencing an overdose. This initiative by Walgreens to increase the availability of naloxone has the potential to save many lives and make a significant impact in combatting the opioid epidemic.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.